SCYX news

SCYNEXIS appointed Dr. Steven K. Burke, an expert in chronic kidney disease, to its Board of Directors on September 18, 2026. The addition of Burke's extensive development expertise is expected to support the company’s clinical progress and strategic goals.

SCYNEXIS named Sanjay Subramanian as its new CFO, effective September 9, 2026, replacing retiring CFO Ivor Macleod. This leadership change signals a strategic shift as the company advances its rare disease pipeline.

SCYNEXIS approved a certificate of amendment authorizing an 8-for-1 reverse stock split of its common stock, reducing authorized shares to 18.75 million. The restructuring affects outstanding share count and per-share pricing metrics.